Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
PONVORY (PONESIMOD) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
PONVORY
NDA
Get alerts
PONESIMOD | N213498 | VANDA PHARMACEUTICALS INC
10 strengths
5 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Price Trends
Medicare D
Approvals
Label
Products
Patent Timeline
5 unique patents, 1 exclusivity by expiration date
All strengths
2MG
3MG
4MG
5MG
6MG
7MG
8MG
9MG
10MG
20MG
Active (5)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
Today
RE43728
Nov. 16, 2029
9062014
May. 6, 2032
10220023
Dec. 10, 2035
11951097
Oct. 10, 2042
12336980
Dec. 10, 2035
NCE
Mar. 18, 2026
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (10)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 2MG
RLD
5 patents
1 exclusivity
▴
TABLET;ORAL | Approved: Mar 18, 2021
Patents (5)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
RE43728
Nov 16, 2029
—
Yes
Yes
—
—
9062014
May 6, 2032
—
Yes
Yes
U-2774
TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
—
10220023
Dec 10, 2035
—
—
—
U-3103
TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
—
11951097
Oct 10, 2042
—
—
—
U-3891
TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS BEING TREATED WITH A BETA-BLOCKER OR IN ADULTS REINITIATING TREATMENT
—
12336980
Dec 10, 2035
—
—
—
U-3103
TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
—
Exclusivities (1)
Code
Date
Status
NCE
Mar 18, 2026
Expired
#002 — 3MG
RLD
5 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Mar 18, 2021
#003 — 4MG
RLD
5 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Mar 18, 2021
#004 — 5MG
RLD
5 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Mar 18, 2021
#005 — 6MG
RLD
5 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Mar 18, 2021
#006 — 7MG
RLD
5 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Mar 18, 2021
#007 — 8MG
RLD
5 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Mar 18, 2021
#008 — 9MG
RLD
5 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Mar 18, 2021
#009 — 10MG
RLD
5 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Mar 18, 2021
#010 — 20MG
RLD
5 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Mar 18, 2021